Sechenov Medical Journal

Advanced search

Peripartum cardiomyopathy (clinical case)


Introduction. Peripartum cardiomyopathy (PPKMP) is a rare cause of heart failure (CHF) in healthy women during pregnancy and within 5 months after delivery.

Case report. A 33-year-old female patient, a native of Tajikistan, first developed shortness of breath and edema of the lower extremities at the 35th week of her third pregnancy. Cesarean section was performed at 39 weeks. Symptoms progressed within 3 months of the postpartum period, hepatomegaly, ascites and hydrothorax appeared. Echocardiography revealed heart chambers dilation, reduced left ventricular ejection fraction (26%), diffuse hypokinesis. The diagnosis of PPCM was established. Perindopril, bisoprolol, spironolactone, furosemide, bromocriptine, heparin were prescribed. The severity of HF symptoms decreased significantly during 12 days of treatment.

Discussion. PPCM is a diagnosis of exclusion. Myocarditis, dilated and ischemic cardiomyopathy were considered in the differential diagnosis. The factors associated with increased risk of PPCM were age over 30 years, multiparity, preeclampsia. The clinical effect of bromocriptine confirms the diagnosis.

About the Authors

Yu. V. Ilina
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Yulia V. Ilina, MD, PhD, Associate Professor, Therapy Department

8/2, Trubetskaya str., Moscow, 119991
Tel.: +7 (495) 623-13-76 

T. A. Fedorova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Tatiana A. Fedorova, MD, PhD, DMSc, Professor, Therapy Department

8/2, Trubetskaya str., Moscow, 119991

N. V. Loshchits
Moscow city clinical hospital named after S. P. Botkin of the Department of health of the City of Moscow
Russian Federation

Natalia V. Loshchits, Head, Therapy Department № 2

5, 2nd Botkinskiy travel, Moscow, 125284

V. V. Vanhin
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Vera V. Vankhin, clinical resident, Therapy Department

8/2, Trubetskaya str., Moscow, 119991


1. Gouley B.A., McMillan T.M., Bellet S. Idiopathic myocardial degeneration associated with pregnancy and especially the peripartum. American Journal of the Medical Sciences. 1937; 19: 185–99.

2. Sliwa K., Hilfiker-Kleiner D., Mebazaa A., et al. EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. European Journal of Heart Failure. 2014; 16(5): 583–91. PMID: 24591060

3. 2018 EOK Rekomendatsii po diagnostike i lecheniyu serdechnososudistykh zabolevanii vo vremya beremennosti. [2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy] Russian Journal of Cardiology. 2019; 6: 151–228 (In Russian).

4. Hilfiker-Kleiner D., Kaminski K., Podewski E., et al. Сathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007; 128(3): 589–600. PMID: 17289576

5. Sliwa K., Forster O., Libhaber E., et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006; 27(4): 441–6. PMID: 16143707

6. Forster O., Hilfiker-Kleiner D., Ansari A.A., et al. Reversal of IFN-gamma, oxLDL and prolactinserum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2008; 10(9): 861–8. PMID: 18768352

7. Sliwa K., Skudicky D., Bergemann A., et al. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. Journal of the American College of Cardiology. 2000; 35(3): 701–5. PMID: 10716473

8. Sliwa K., Forster O., Tibazarwa K., et al. Long-term outcome of peripartum cardiomyopathy in a population with high seropositivity for human immunodeficiency virus. Int J Cardiol. 2011; 47(2): 202–8. Published online aheadof print 12 September 2009. PMID: 19751951

9. Haghikia A., Kaya Z., Schwab J., et al. Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. Basic Res Cardiol. 2015; 110(6): 60. PMID: 26519371

10. Warraich R.S., Sliwa K., Damasceno A., et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J. 2005; 150(2): 263–9. PMID: 16086928

11. Sliwa K., Hilfiker-Kleiner D., Petrie M.C., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010; 12: 767–78.

12. Sliwa K., Blauwet L., Tibazarwa K., et al. Evaluation of b tine in the treatment of acute severe peripartum cardiomyopathy: A proof-of-concept pilot study. Circulation. 2010; 121(13): 146573. PMID: 20308616

13. Hilfiker-Kleiner D., Haghikia A., Berliner D., et al. Bromocriptine for the treatment of peripartum cardiomyopathy: A multicentre randomized study. Eur Heart J. 2017; 38(35): 2671–9. PMID: 28934837

14. Haghikia A., Podewski E., Berliner D., et al. Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. Clin Res Cardiol. 2015; 104(11): 911–7. PMID: 26026286

15. Davis M.B., Arany Z., McNamara D.M., el al. JACC State-of-the-Art Review. Peripartum Cardiomyopathy. Am Coll Cardiol 2020; 75(2): 207–21.


Views: 11201

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2218-7332 (Print)
ISSN 2658-3348 (Online)